<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138164</url>
  </required_header>
  <id_info>
    <org_study_id>LIGAND-PIND-123</org_study_id>
    <secondary_id>UCLA-0412087-01</secondary_id>
    <secondary_id>CDR0000439451</secondary_id>
    <nct_id>NCT00138164</nct_id>
  </id_info>
  <brief_title>Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Multicenter Study of Ontak® (Denileukin Diftitox) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as denileukin diftitox, may be able to carry&#xD;
      cancer-killing substances directly to non-Hodgkin's lymphoma cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating&#xD;
      patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of denileukin diftitox, in terms of objective response and time&#xD;
           to progression, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the 1-year overall survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive denileukin diftitox IV over 20-80 minutes on days 1-3, 8, 15, 22, 29, 36,&#xD;
      43, 50, 57, 64, 71, 78, 85, 92, and 99 (weeks 1-16) in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients achieving a partial response at week 16 may continue&#xD;
      treatment once monthly for up to 8 additional doses or until a complete response (CR) is&#xD;
      achieved. Patients achieving a CR (at any time) receive 2 additional monthly doses of&#xD;
      denileukin diftitox beyond CR.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective clinical response (complete or partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of 1 of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma&#xD;
&#xD;
               -  Follicular lymphoma (grades 1-3)&#xD;
&#xD;
               -  Small lymphocytic lymphoma&#xD;
&#xD;
               -  Transformed B-cell lymphoma&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
               -  Disease failed to respond to or progressed after ≥ 2 prior treatment regimens&#xD;
                  (e.g., high-dose therapy [HDT] with stem cell transplantation [SCT]*) NOTE:&#xD;
                  *Patients who have received HDT with SCT are considered to have diminished bone&#xD;
                  marrow reserve&#xD;
&#xD;
          -  Diminished bone marrow reserve AND/OR mild to moderate cytopenia, meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3 but &lt; 1,500/mm^3 (growth factor&#xD;
                  independent)&#xD;
&#xD;
               -  WBC ≥ 2,000/mm^3 but &lt; 4,000/mm^3 (growth factor independent)&#xD;
&#xD;
               -  Platelet count ≥ 40,000/mm^3 (25,000/mm^3 if thrombocytopenia is secondary to&#xD;
                  marrow involvement by lymphoma) but &lt; 150,000/mm^3 (platelet transfusion&#xD;
                  independent)&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lymph node or tumor mass ≥ 4 cm&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 16 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2 times ULN&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  No history of veno-occlusive disease of the liver&#xD;
&#xD;
          -  No chronic hepatitis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
          -  No ventricular tachycardia&#xD;
&#xD;
          -  No fibrillation&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No active GVHD ≥ grade 2 within the past 6 months&#xD;
&#xD;
          -  No other serious medical illness or active infection that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No known hypersensitivity to denileukin diftitox or any of its components (e.g.,&#xD;
             diphtheria toxin, interleukin-2, or their excipients)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except successfully treated carcinoma in&#xD;
             situ of the cervix or basal cell carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior allogeneic SCT&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  No concurrent corticosteroids for the treatment of NHL&#xD;
&#xD;
          -  Concurrent corticosteroids allowed for the following conditions:&#xD;
&#xD;
               -  Tapering doses of corticosteroids for resolving graft-versus-host disease (GVHD)&#xD;
&#xD;
               -  Low-dose maintenance corticosteroids for the treatment of an autoimmune disorder&#xD;
&#xD;
               -  Corticosteroids as premedication prior to denileukin diftitox administration or&#xD;
                  as transient treatment for hypersensitivity reactions&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the only site of evaluable disease unless disease progression&#xD;
             has occurred at that site&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior antilymphoma therapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent experimental therapy, including&#xD;
             approved drugs tested in an investigational setting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren C. Pinter-Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

